Form 4: Allogene Therapeutics CFO Acquires Shares and Stock Options

Allogene Therapeutics' Chief Financial Officer, Geoffrey M. Parker, acquired shares and stock options on January 24, 2025.

Summary

• Geoffrey M. Parker, the Chief Financial Officer of Allogene Therapeutics, acquired 173,913 shares of common stock on January 24, 2025.
• These shares were acquired at a price of $0.
• Following this transaction, Mr. Parker directly owns 1,305,901 shares of common stock.
• Mr. Parker also acquired 614,844 stock options with an exercise price of $1.94 on the same date.
• These options vest over time, with 25% vesting on January 24, 2026, and the remainder vesting in 36 equal monthly installments thereafter.
• The stock options expire on January 24, 2035.

Sentiment

Score: 6

Explanation: The document is a routine filing of insider transactions. It is neither particularly positive nor negative, but the acquisition of shares by the CFO could be seen as a mild positive.

Positives

• The acquisition of shares and stock options by the CFO could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who trade in their company's stock. It provides transparency into the transactions of key personnel.

Comparison to Industry Standards

• The vesting schedule of the stock options is typical for executive compensation packages in the biotechnology industry.
• The acquisition of shares at $0 is likely due to the grant of restricted stock units as part of the compensation package.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the CFO's increased stake in the company.

Key Dates

Keywords

Allogene Therapeutics, Geoffrey M. Parker, stock options, common stock, insider trading, SEC Form 4, equity